NorthStar Trial Analysis at ELCC 2026: Local Consolidative Therapy in EGFR-Mutant NSCLC
oncodaily - The management of metastatic EGFR-mutant non-small cell lung cancer (NSCLC) has been transformed by the introduction of third-generation EGFR tyrosine kinase inhibitors, particularly osimertinib. While systemic therapy achieves meaningful disease […]
AI Summary: ELCC 2026 brought together clinicians and investigators to present pivotal lung‑cancer studies, including localized consolidative therapy, SBRT sequencing with immunotherapy, and trials addressing under‑represented KRAS and EGFR populations. The conference highlighted survival and tumor‑control signals, networked international collaborators, and emphasized real‑world applicability — proving once again that conferences are where hope meets peer review.
- At ELCC: late‑breaking trials reshaping clinical practice (6)
- OTHER: misc lung oncology studies, regulatory and surgical updates (8)
- Precision push: molecular testing, KRAS degraders, ADC collaborations advancing care (6)
- Voices from ELCC: clinicians share breakthroughs and practical takeaways (17)
- All Other Stories